Table 1 Patient characteristics and event distribution in relation to patient, clinical, tumor and treatment factors
Characteristic | No. of patients |
|---|---|
Age, y | |
[29-39] | 52 (5.7%) |
[40-49] | 227(24.7%) |
[50-69] | 512(55.7%) |
≥ 70 | 128(13.9%) |
Total | 919 |
Histological size of the tumor (mm) | |
25th quartile | 11.0 |
Median | 15.0 |
75th quartile | 20.0 |
Range | 1-45 |
Total | 881 |
Extensive intraductal component (EIC) | |
-No | 866 (94.2%) |
-Yes | 53 (5.8%) |
Total | 919 |
Grade | |
- Grade 1 | 324 (40.0%) |
- Grade 2 | 355 (43.8%) |
- Grade 3 | 131 (16.2%) |
Total | 810 |
# positive nodes | |
- 0 | 549 (62.8%) |
- 1-3 | 247 (28.3%) |
- ≥4 | 78 (8.9%) |
Total | 874 |
Lympho-vascular invasion | |
- No | 667 (75.8%) |
- Yes | 213 (24.2%) |
Total | 880 |
Surgical excision margin status | |
- Clear (ref) | 549 (63.7%) |
- Invasion | 313 (36.3%) |
Total | 862 |
Progesterone receptor status | |
- Positive | 459 (55.0%) |
- Negative | 376 (45.0%) |
Total | 835 |
Estrogen receptor status | |
- Positive | 657 (21.5%) |
- Negative | 180 (78.5%) |
Total | 837 |
Treatment combination | |
- Radiotherapy | 586 (63.8%) |
- Radio- and chemotherapy | 129 (14.1%) |
- Radio- and hormonal therapy | 183 (19.9%) |
- Radio- and chemo- and hormonal therapy | 20 (2.2%) |
Total | 918 |